Soft-tissue venous malformations in children: percutaneous sclerotherapy with Ethibloc.
Thirty-eight children with soft-tissue venous malformations (VMs) were treated with percutaneous injection of a new fibrosing agent (Ethibloc). The technique, results, side effects, and complications are detailed. Direct puncture of the VM allows evaluation of the draining venous system and direct injection of Ethibloc. This procedure alone or associated with surgery led to achievement of good or excellent results in 74% of the cases (complete cure in 50%), with minimal side effects and no major complications.
Dubois
J M
JM
Department of Pediatric Radiology, Hôpital des Enfants Malades, Paris, France.
Sebag
G H
GH
De Prost
Y
Y
Teillac
D
D
Chretien
B
B
Brunelle
F O
FO
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003973:Diatrizoate; D004338:Drug Combinations; D005227:Fatty Acids; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010690:Phlebography; D011409:Propylene Glycols; D011506:Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods; D014680:Veins / Q000002:abnormalities*; D015028:Zein
D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D011506:Proteins; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution